USP39 and hepatocellular carcinoma: In addition, downregulation of ZEB1 was dramatically reversed in USP39 knockdown HCC cells (HepG2) treated with MG132 (an inhibitor of the ubiquitin–proteasome pathway) (Fig. 3E).